ARYX THERAPEUTICS COM STK USD0.001 (ARYX)

0.00
0.00 75.00
OTC
Prev Close 0.00
Open 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.01
Volume 5.29K
Exchange OTC
Shares Outstanding 33.46B
Market Cap 117.10K
Div & Yield N.A. (N.A)

Latest News

ARYx Therapeutics To Transfer To The NASDAQ Capital Market

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it has been notified by The NASDAQ Stock Market (“NASDAQ”) that the listing of its common stock will be transferred from The NASDAQ Global Market to The ...

ARYx Therapeutics Provides Update On Company Status

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported on its on-going strategic corporate efforts to optimize the value of its assets on behalf of the company’s stockholders.

5 Drug Stock Losers of 2010

Clinical trial failures, poor sales and crushing debt pummeled shares of Vermillion, Oxigene and Angiotech in 2010.

ARYx Therapeutics Reports Third Quarter Results

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today provided an update on its business operations and released its financial results for the third quarter of 2010.

ARYx Therapeutics Receives NASDAQ Notice Of Non-Compliance

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that ARYx was notified October 5, 2010 by the staff of the NASDAQ Stock Market that it has not regained compliance with the $50 million minimum market ...

ARYx Therapeutics Secures Interim Financing

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders.

ARYx Announces Resignation Of Peter G. Milner, President Research And Development

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that Peter G.

ARYx Reports First Quarter 2010 Results Of Operations

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided an update on its business activities for the first quarter ended March 31, 2010.

ARYx Therapeutics Schedules First Quarter 2010 Results Conference Call

ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today that a conference call to discuss first quarter 2010 results and to provide a general business update will be held on Thursday, May...

ARYx To Present At Cowen And Company Annual Health Care Conference

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at the Cowen and Company 30 th Annual Health Care Conference in Boston on March 9, 2010 at 1:30 pm Eastern.

Biotech Stock Mailbag: BioSante Pharma

Biotech Stock Mailbag: BioSante Pharma

Biotech watchdog Adam Feuerstein addresses readers' questions about BioSante and other healthcare stocks.

ARYx Therapeutics Retains Cowen And Company To Explore Strategic Options

ARYx Therapeutics Inc. (NASDAQ: ARYX), a biopharmaceutical company, today announced that it has retained Cowen and Company to explore strategic options for ARYx.

Revlon, Micromet: Early Volume Plays

Several small-cap stocks were poised to move on above-average volume during Thursday's session.

Biotech ARYx Therapeutics Reports Smaller 2Q Loss

Biotechnology company ARYx Therapeutics reports smaller 2nd-quarter loss, no revenue

Last Minute Sprint Overcomes Sellers

Debra Borchardt and co-host Liz Trotta break down the market with guests David Peltier, Scott Moritz, and Adam Feuerstein.

Aryx Keeps Biotech Investors Humble

Amgen is up big on its denosumab victory, while Aryx Therapeutics is down bigger on new blood-clotting data.

Stock Search: Bank of American, Citigroup

Bank of America and Citigroup are holding the top spots on TheStreet.com's stock-search list today. New entries to the list include Cell Therapeutics, ARYx Therapeutics, Hemispherx Biopharma and Boeing.

Biotech Calendar: Key Clinical Trial Dates

A quick and dirty guide to upcoming clinical trial dates for drug and biotech companies.

Aryx Therapeutics 1Q Loss Widens On Revenue Drop

Aryx Therapeutics' 1st-quarter loss widens on revenue drop after partnership ends